335 related articles for article (PubMed ID: 30977808)
1. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
2. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Feb; 47(3):412-420. PubMed ID: 29181838
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
5. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
Butt AA; Yan P; Shaikh OS; Freiberg MS; Lo Re V; Justice AC; Sherman KE;
J Viral Hepat; 2015 Sep; 22(9):691-700. PubMed ID: 25524834
[TBL] [Abstract][Full Text] [Related]
6. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
Butt AA; Yan P; Marks K; Shaikh OS; Sherman KE;
Aliment Pharmacol Ther; 2016 Oct; 44(7):728-37. PubMed ID: 27459341
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES.
Butt AA; Yan P; Aslam S; Sherman KE; Siraj D; Safdar N; Hameed B
Int J Infect Dis; 2020 Mar; 92():184-188. PubMed ID: 31978574
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
9. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
10. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
11. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA
Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416
[TBL] [Abstract][Full Text] [Related]
12. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
13. Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: Results from ERCHIVES.
Butt AA; Yan P;
J Viral Hepat; 2021 Jun; 28(6):916-924. PubMed ID: 33763947
[TBL] [Abstract][Full Text] [Related]
14. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Liver Int; 2018 Aug; 38(8):1411-1417. PubMed ID: 29271562
[TBL] [Abstract][Full Text] [Related]
15. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 May; 36(5):651-8. PubMed ID: 26616353
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
19. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
